Explore the vast range of titles available.

Purpose This study aimed to analyze whether a regimen of aromatase inhibitor (AI) could reduce the occurrence of smooth endoplasmic reticulum clusters (sERCs) in oocytes. Method(s) The AI and the clomiphene citrate (CC) regimens were compared, regarding the sERC (+) rates and the serum estradiol and progesterone levels on the date of hCG administration, and the duration of AI, CC, and hMG administration. Result(s) The occurrence of sERCs in oocytes from patients treated with AI was significantly higher than that in oocytes from those treated with CC. Both the serum estradiol and progesterone levels were found to be significantly higher in sERC (+) than in sERC (‐) cycles. With regard to the CC cycles, no significant differences were detected. The duration of AI and hMG administration was longer for sERC (+) than for sERC (‐) cycles. Conclusion As AI did not reduce the occurrence of sERCs, the elevation of estradiol may not be the cause of sERC occurrence but a consequence. Considering the higher levels of progesterone and longer duration of hMG in sERC (+) cycles, the negative effects of premature luteinization, which frequently occur with the AI protocol, should be investigated further.

Purpose This study aimed to analyze whether the presence of refractile bodies (RFs) negatively affects fertilization, embryo development, and/or implantation rates following intracytoplasmic sperm injection (ICSI). Methods This retrospective embryo cohort study involved a total of 272 patients undergoing ICSI treatment of blastocyst cryopreservation. Results In the study, no significant differences were found regarding 2PN formation rates between RF(+) (76.5%) and RF(−) oocytes (77.2%). However, the blastocyst formation rate on Day 5 in RF(+) oocytes was 45.8%, which was significantly lower than that of 52.2% in RF(−) oocytes (aOR 0.74, 95% CI 0.59‐0.93, P = .011). Implantation rates were also significantly lower in RF(+) oocytes (24.2%) as compared to RF(−) oocytes (42.2%) (aOR 0.46, 95% CI 0.26‐0.78, P = .005). Furthermore, the implantation rate of RF(+) oocytes (28.6%), when high‐quality blastocysts were transferred, was significantly lower than that of RF(−) oocytes (46.1%) (aOR 0.50, 95% CI 0.25‐0.96, P = .043). Conclusion Our results suggest that oocytes with the presence of RFs have a lower potential for blastocyst development. Even when they develop into high‐quality blastocysts, the chances of implantation are reduced. Oocytes with the presence of RFs have a lower potential to develop into blastocysts, and even when they develop into high‐quality blastocysts, the chances of implantation are reduced.

Correction of: https://www.researchprotocols.org/2025/1/e78612

Increased appetite and weight gain are common adverse effects of glucocorticoid (GC) therapy in patients with systemic lupus erythematosus (SLE). Concerns about appearance-related changes due to weight gain can reduce medication adherence. Moreover, the complex interplay among GCs, mood changes, sleep disturbances, and appetite can influence eating behaviors. Daily data collection using an ecological momentary assessment (EMA) and analysis of interrelations may help clarify these dynamics. Furthermore, real-time feedback based on daily eating behavior may help patients regulate appetite and eating patterns. Accordingly, we developed Mogu!☆Log, a smartphone-based application that enables daily self-reporting of eating behaviors, appetite, and mood, and provides graphical feedback on meal frequency and perceived control over eating. This study presents a protocol for a pilot randomized controlled trial (RCT) designed to evaluate the effects of real-time feedback on eating behaviors using the Mogu!☆Log app among patients with newly diagnosed SLE who had started GC therapy. This multicenter study recruited Japanese patients with newly diagnosed SLE who had started GC therapy across 15 hospitals with rheumatology services. Participants were randomly assigned (1:1) to two groups: (1) the immediate feedback group, which receives graphical feedback on meal frequency and perceived control over eating starting from day 1, and (2) the delayed feedback group, which uses the same app without feedback for the first 14 days and begins receiving identical feedback from day 15. Participants enter data daily from day 1 to day 21 after randomization. The primary outcome is the mean number of meals on day 14 after GC initiation. Secondary outcomes include the loss-of-control-over-eating score and the five-item visual analog scale-based appetite score, both recorded on day 14. Between-group mean differences will be analyzed using t-tests. The target sample size is 60. In an embedded observational Study Within a Trial (SWAT), linear mixed models will examine whether GC dose influences appetite scores through mood and sleep changes. We hypothesized that participants receiving immediate feedback will have fewer meals on day 14, reduced loss of control over eating, and better appetite scores. The study received funding in April 2019, April 2022, and April 2024. Recruitment began in October 2024, and as of May 2025, 17 participants were enrolled. Data collection is expected to be completed by March 2027, with data analysis yet to begin. Results will be submitted for publication and reported to the UMIN registry in summer 2027. This pilot trial will provide foundational data on the feasibility and efficacy of smartphone-based real-time feedback in managing GC-induced appetite increase in patients with SLE. These findings may contribute to the growing body of literature on app-based interventions for medication-related adverse effects. UMIN Clinical Trials Registry UMIN000052113 https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000059479.

The MYO7A gene is known to be responsible for both syndromic hearing loss (Usher syndrome type1B:USH1B) and non-syndromic hearing loss including autosomal dominant and autosomal recessive inheritance (DFNA11, DFNB2). However, the prevalence and detailed clinical features of MYO7A -associated hearing loss across a large population remain unclear. In this study, we conducted next-generation sequencing analysis for a large cohort of 10,042 Japanese hearing loss patients. As a result, 137 patients were identified with MYO7A -associated hearing loss so that the prevalence among Japanese hearing loss patients was 1.36%. We identified 70 disease-causing candidate variants in this study, with 36 of them being novel variants. All variants identified in autosomal dominant cases were missense or in-frame deletion variants. Among the autosomal recessive cases, all patients had at least one missense variant. On the other hand, in patients with Usher syndrome, almost half of the patients carried biallelic null variants (nonsense, splicing, and frameshift variants). Most of the autosomal dominant cases showed late-onset progressive hearing loss. On the other hand, cases with autosomal recessive inheritance or Usher syndrome showed congenital or early-onset hearing loss. The visual symptoms in the Usher syndrome cases developed between age 5–15, and the condition was diagnosed at about 6–15 years of age.

Increased appetite and weight gain are common adverse effects of glucocorticoid therapy in patients with systemic lupus erythematosus (SLE). Concerns about appearance-related changes due to weight gain can reduce medication adherence. Moreover, the complex interplay among glucocorticoids, mood changes, sleep disturbances, and appetite can influence eating behaviors. Daily data collection using ecological momentary assessment and analysis of interrelations may help clarify these dynamics. Furthermore, real-time feedback based on daily eating behavior may help patients regulate appetite and eating patterns. Accordingly, we developed Mogu!☆Log, a smartphone-based app that enables daily self-reporting of eating behaviors, appetite, and mood and provides graphical feedback on meal frequency and perceived control over eating. This paper presents a protocol for a pilot randomized controlled trial designed to evaluate the effects of real-time feedback on eating behaviors using the Mogu!☆Log app among patients with newly diagnosed SLE who had started glucocorticoid therapy. This multicenter study recruited Japanese patients with newly diagnosed SLE who had started glucocorticoid therapy across 15 hospitals with rheumatology services. Participants were randomly assigned in a 1:1 ratio to two groups: (1) the immediate feedback group, which receives graphical feedback on meal frequency and perceived control over eating starting from day 1, and (2) the delayed feedback group, which uses the same app without feedback for the first 14 days and begins receiving identical feedback from day 15. Participants enter data daily from day 1 to day 21 after randomization. The primary outcome is the mean number of meals on day 14 after glucocorticoid initiation. Secondary outcomes include the loss-of-control-over-eating score and a 5-item visual analog scale-based appetite score, both recorded on day 14. Between-group mean differences will be analyzed using 2-tailed t tests. The target sample size is 60. In an embedded observational \"study within a trial,\" linear mixed models will examine whether glucocorticoid dose influences appetite scores through mood and sleep changes. We hypothesized that participants receiving immediate feedback will have fewer meals on day 14, reduced loss of control over eating, and better appetite scores. The study received funding in April 2019, April 2022, and April 2024. Recruitment began in October 2024, and 17 participants had been enrolled as of May 2025. Data collection is expected to be completed by March 2027; data analysis has yet to begin. Results will be submitted for publication and reported to the University Hospital Medical Information Network (UMIN) registry in the summer of 2027. This pilot trial will provide foundational data on the feasibility and efficacy of smartphone-based real-time feedback in managing glucocorticoid-induced appetite increase in patients with SLE. These findings may contribute to the growing body of literature on app-based interventions for medication-related adverse effects.